"It's really irrational to take a brand new, untested, untried technology from a company that's completely shielded from immunity [she meant liability] when on the other hand I've got a drug that's 60 years old, that's been given billions of times and is completely safe for all age groups."
"Antibody dependent enhancement" - with SARS-cov-1 in early 2000's, they could not come up with a vaccine because of this - in animal studies, animals did OK following the 2 doses of vaccine, but then when exposed to the Covid virus, they died.
"Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials.'
"It's really irrational to take a brand new, untested, untried technology from a company that's completely shielded from immunity [she meant liability] when on the other hand I've got a drug that's 60 years old, that's been given billions of times and is completely safe for all age groups."
"Antibody dependent enhancement" - with SARS-cov-1 in early 2000's, they could not come up with a vaccine because of this - in animal studies, animals did OK following the 2 doses of vaccine, but then when exposed to the Covid virus, they died.
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies (Oct. 2020) https://pubmed.ncbi.nlm.nih.gov/32908214/
"Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials.'
Yes! This!!